---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-242909"
form_type: "8-K"
ticker: "DCTH"
cik: "0000872912"
company_name: "DELCATH SYSTEMS, INC."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:19:39.120913+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Delcath: Q3 prelim rev $20.5M, net income $0.8M; CHOPIN trial meets endpoint

## Summary
- Prelim Q3 rev $20.5M ($19.2M HEPZATO, $1.3M CHEMOSAT); net income $0.8M; adj EBITDA $5.3M; cash $88.9M, no debt.
- FY2025 rev guidance raised to $83-85M, reflecting ~150% treatment volume increase over 2024.
- CHOPIN trial met primary endpoint: 1-yr PFS 54.7% (combo) vs 15.8% (PHP alone); HR 0.34, p<0.001.
- Secondary endpoints: 2-yr OS 49.6% vs 22.1% (HR 0.39, p=0.006); ORR 76.3% vs 39.5% (p<0.001).
- Grade 3+ AEs higher in combo (81.6% vs 40.5%) but manageable; no new safety signals.

## SEC filing metadata
- accession: 0001193125-25-242909
- form_type: 8-K
- ticker: DCTH
- cik: 0000872912
- company_name: DELCATH SYSTEMS, INC.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872912/000119312525242909/0001193125-25-242909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872912/000119312525242909/d51469d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-242909
- JSON: https://secwatch.observer/filing/0001193125-25-242909.json
- Plain text: https://secwatch.observer/filing/0001193125-25-242909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.